Telios Pharmaceuticals
Executive Summary
Ono Pharmaceutical Co. Ltd. (Osaka) acquires "significant equity investment" and is supplying "several million dollars" to privately held San Diego-based R&D firm to develop Transforming Growth Factor-beta-based drugs. Ono will fund R&D and clinical testing of TGFb drugs that block "abnormal tissue scarring involved in kidney inflammation, pulmonary fibrosis, liver cirrhosis and other fibrotic disorders" in return for marketing rights in Japan, Taiwan and South Korea. Telios retains rights elsewhere. Agreement also gives Ono first right of refusal in the same countries for all other Telios human drug products -- excluding firm's blood-clot inhibitors and (ITALICS)Telio-derm(END ITALICS) wound healing gel ("The Pink Sheet" Aug. 13, T&G-9). Ono already has Asian license for Telios' "dry eye" product (ITALICS)Oculos,(END ITALICS) which is in development.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.